• No results found

A Study on Clinical and Cardiovascular Profile of Rheumatoid Arthritis Patients and Its Correlation with Disease Activity

N/A
N/A
Protected

Academic year: 2022

Share "A Study on Clinical and Cardiovascular Profile of Rheumatoid Arthritis Patients and Its Correlation with Disease Activity"

Copied!
106
0
0

Loading.... (view fulltext now)

Full text

(1)

A STUDY ON CLINICAL & CARDIOVASCULAR PROFILE OF RHEUMATOID ARTHRITIS PATIENTS & IT’S CORRELATION

WITH DISEASE ACTIVITY

DISSERTATION SUBMITTED TO THE TAMILNADU DR.M.G.R. MEDICAL UNIVERSITY, CHENNAI In partial fulfilment of the requirements for the degree of

M.D. BRANCH – I (GENERAL MEDICINE)

DEPARTMENT OF GENERAL MEDICINE TIRUNELVELI MEDICAL COLLEGE HOSPITAL

TIRUNELVELI – 627011

(2)

BONAFIDE CERTIFICATE

This is to certify that the dissertation entitled “A STUDY ON CLINICAL &

CARDIOVASCULAR PROFILE OF RHEUMATOID ARTHRITIS PATIENTS & IT’S CORRELATION WITH DISEASE ACTIVITY”

submitted by Dr. R.NANDINI @ KIRUTHIKA, to the Tamilnadu Dr. M.G.R Medical University, Chennai, in partial fulfillment of the requirement for the award of M.D. Degree Branch – I (General Medicine) is a bonafide research work carried out by her under direct supervision & guidance.

Professor & Head of the Department, Department of General Medicine

Tirunelveli Medical College, Tirunelveli.

Unit Chief,

Department of General Medicine Tirunelveli Medical College,

Tirunelveli.

(3)

CERTIFICATE BY THE DEAN

I hereby certify that this dissertation entitled “A STUDY ON CLINICAL & CARDIOVASCULAR PROFILE OF RHEUMATOID ARTHRITIS PATIENTS & IT’S CORRELATION WITH DISEASE ACTIVITY” is a record of work done byDr. R.NANDINI @ KIRUTHIKA, in the Department of General Medicine, Tirunelveli Medical College, Tirunelveli, during her postgraduate degree course period from 2016- 2019.

This work has not formed the basis for previous award of any degree.

Date :

Place : TIRUNELVELI The DEAN

Tirunelveli Medical College, Tirunelveli - 627011.

(4)

DECLARATION

I solemnly declare that the dissertation entitled “A STUDY ON CLINICAL & CARDIOVASCULAR PROFILE OF RHEUMATOID ARTHRITIS PATIENTS & IT’S CORRELATION WITH DISEASE ACTIVITY” is done by me at Tirunelveli Medical College Hospital, Tirunelveli Under the guidance and supervision of Prof.Dr.G.Rathnakumar M.D, the dissertation is submitted to The Tamilnadu Dr. M.G.R. Medical University towards the partial fulfilment of requirements for the award of M.D.

Degree (Branch I) in General Medicine.

Place: Tirunelveli

Date: Dr.R.NANDINI @ KIRUTHIKA

Postgraduate Student, M.D General Medicine, Department of General Medicine,

Tirunelveli Medical College Tirunelveli.

(5)

CERTIFICATE – II

This is to certify that this dissertation work entitled “A STUDY ON CLINICAL & CARDIOVASCULAR PROFILE OF RHEUMATOID ARTHRITIS PATIENTS & IT’S CORRELATION WITH DISEASE ACTIVITY” of the candidate Dr.R.NANDINI @ KIRUTHIKA with registration Number 201611357 for the award of M.D. Degree in the branch of GENERAL MEDICINE (I). I personally verified the urkund.com website for the purpose of plagiarism check. I found that the uploaded thesis file contains from introduction to conclusion page and result shows 6 percentage of plagiarism in the dissertation.

Guide & Supervisor sign with Seal.

(6)
(7)
(8)

ACKNOWLEDGEMENT

I wish to express my heartfelt gratitude to our Dean Prof.Dr. S. M. .Kannan M.S., MCh., Tirunelveli Medical College for allowing me to do the

study in this institution.

I would like to express my humble thanks to our professor & Head of the Department Prof .Dr .M.Ravichandran M.D., Department of General Medicine.

I express my sincere thanks to my renowned teacher and my guide Dr.G.Rathnakumar M.D., Professor, Department of General Medicine, Tirunelveli Medical College for his guidance, valuable suggestions and constant encouragement throughout the study.

I express my sincere thanks to my former professors, Dr.S.Arumugapandian @ Mohan, M.D., Dr.S.S.Nazar M.D., for their constant support, encouragement and suggestions which helped me greatly to expedite this dissertation .

I am greatly obliged to Dr.Vidya M.D, D.M(Rheumatology), Dr.S.Jawahar M.D, Dr.Govindarajan M.D, Dr.Rajkumar M.D, Assistant Professors, Dept .of General Medicine for their valuable suggestions in

(9)

CONTENT

S.NO TITLE PAGE.NO

1. INTRODUCTION 1

2. AIM AND OBJECTIVES OF THE STUDY 2

3. REVIEW OF LITERATURE 3

4. MATERIALS AND METHODS 39

5. RESULTS 43

6. DISCUSSION 76

8. CONCLUSION 81

9. LIMITATIONS OF THE STUDY 83

10. BIBILIOGRAPHY 11. MASTER CHART

(10)

INTRODUCTION

Rheumatoid arthritis (RA) is a chronic inflammatory disorder, characterised by both articular and extra - articular manifestations. The chronic subclinical inflammation in rheumatoid arthritis contributes to accelerated atherosclerosis and various cardiovascular events. A recent study showed that 50% mortality in rheumatoid arthritis is due to cardiovascular disease related deaths. RA is associated with disability, shortened life expectancy, and increased mortality as compared to the general population. Cardiovascular events seems to occur approximately a decade earlier in Rheumatoid arthritis patients like that in diabetes mellitus.

Moreover, like Diabetes mellitus and Dyslipidemia, there is an independent association of RA with preclinical and overt cardiovascular disease and most of the time it is silent with unfavourable outcome leading to premature death.

In a study, if the clinical disease activity index score falls by 10, the risk of developing cardiovascular disease decreases by 26% has been formulated. So it is necessary to do screening for cardiovascular disease in all Rheumatoid arthritis patients. Also, the influence of disease activity on development of cardiovascular disease should also be studied.

(11)

AIMS AND OBJECTIVES

1) To study and document the occurrence of various cardiovascular manifestations in Rheumatoid arthritis patients

2) To assess the disease severity in Rheumatoid arthritis patients

3) To correlate and compare the association between disease severity and various clinical and cardiovascular manifestations in rheumatoid arthritis patients

(12)

REVIEW OF LITERATURE

Rheumatoid arthritis is a chronic autoimmune inflammatory disorder, characterised by both articular and extra-articular manifestations. It is a progressive disease characterised by exacerbations and remissions . The disease has various environmental triggering factors and genetic influences.

EPIDEMIOLOGY

 Females are affected more than males in a ratio of 3:1 ; whereas around 60 years of age the ratio equilibrates

 Onset peaks around mid 50s.

 40% of the patients may have extra articular manifestations.

 Risk of Rheumatoid Arthritis is high among Smokers.

ETIOLOGY

 Genetic predisposition plays an important role in this disease. It is due to a shared epitope present on chromosome 6 which encodes the class II Histocompatibility locus; HLA-DRB1*0401, HLA-DRB1*0404, HLA-Dw4, HLA-Dw14.

 Genetic Polymorphisms in genes PTPN22, PADI4, STAT4, TRAFI- C5, CTLA4, Cytokines like TNF –alpha, IFN –gamma disequilibrium have been associated with the occurrence of Rheumatoid arthritis

(13)

 Heavy Tobacco smoking along with genetic predisposition as evidenced by carriage of HLA – DR SE genes have been known to show more citrllinated proteins in bronchoalveolar lavage and subsequent immune reaction leading to anti citrullinated antibodies.

PATHOGENESIS

The cell mediated immunity, mainly CD4 cells are the main culprit behind the activation of cytokines which causes local destruction of synovial membrane & other joint structures.

In Individuals with immune hyper reactivity and genetic predisposition, some unknown trigger activates components of innate immunity such as dendritic cells, macrophages & fibroblast like synoviocytes in joint tissue. Dendritic cells act as antigen presenting cells and activate T and B lymphocytes in central lymphoid organs. These lymphocytes migrate back to joint tissue, enhance and sustain chronic inflammation in both articular and extra articular regions.

CYTOKINE DYSREGULATION

Th1, Th2 and Th17 type of CD4 cells which are activated produce excess cytokines like IFN – gamma, TNF –alpha, IL-4, IL-5, IL-6, IL-17.

These cytokines also suppress regulatory cytokines such as IL -10, IL-35,

(14)

causes synovial inflammation – later becomes chronic and hypertrophic forming a tumour like pannus that invades and causes cartilage destruction, bone erosions and also responsible for extra articular manifestations.

TNF – alpha and IL-1 promote fibroblast proliferation and adhesion.

IL – 6 produces B cell activation and produces inflammatory mediators such as C-Reactive Protein.

Later, Osteoclast and NK cell also plays a role. Overtime, most patients develop erosions within cartilage and bone, narrowing of joint space and peri-articular decalcification usually visualised as radiographic changes in X-ray film.

PATHOGENESIS OF RHEUMATOID ARTHRITIS

(15)

Infectious trigger causes

infiltration of synovial membrane with lymphocytes,macrophages,plasma cells

T cell activation.

T-cells interact with B-cells to cause

production of cytokines, autoantibodies &

B cells acts antigen presenting calls

Proinflammatory cytokines acting on synovial fibroblast

causes swelling of synovial membrane and damage of soft tissues and cartilage

(pannus formation)

local tissue damage and remodelling

neovascularisation and further leucocyte infiltration

and chronic inflammation

(16)

CLINICAL FEATURES:

It includes

 Articular

 Extra articular

ARTICULAR MANIFESTATIONS:

 Usually Presents as Chronic inflammatory symmetric polyarthropathy.

Can occasionally present as oligo or mono arthropathy.

 Affects small joints of hand and feet in symmetric pattern. Also produces chronic irreversible deformities which presents as

 Swan neck deformity – Hyperextension of PIP joint with Flexion of DIP joint

 Boutonniere deformity – Flexion of PIP joint with Hyperextension of DIP joint

 Mallet finger,

 Z line deformity – Subluxation of 1st Metacarpophalangeal joint with hyperextension of first interphalangeal joint.

 boxing glove appearance

 Piano Key movement of ulnar styloid due to tenosynovitis of extensor carpi ulnaris and ulnar styloid inflammation leading to subluxation of distal ulna.

(17)

 Hallux valgus.

 Pes Planovalgus – Flat foot due to involvement of Ankle and Midtarsal joint

 Causes morning stiffness which lasts for 1hour.

 Also presents as synovitis – Flexor tendon more commonly involved which results in

 Decreased range of motion

 Decreased hand grip strength &

 Trigger finger

 Cervical spine (Atlantoaxial joint subluxation) involvement can occur – causes compressive myelopathy

 Aymptomatic Temporomandibular joint involvement can occur Later in disease, shoulders and knees can get affected.

(18)

EXTRA ARTICULAR:

Rheumatoid Nodules

 Subcutaneous Nodules is one of the common extra articular manifestations of rheumatoid arthritis.

 Occurs over extensor aspects of elbow, hand, sacral prominences and over Achilles tendon. Nodules are usually nontender, firm can be adherent to underlying periosteum, tendons or bursae.

 Correlates with Rheumatoid factor positivity, high disease activity and presence of joint erosions.

 May also occur in lungs, can be attached to pleura, pericardium or peritoneum.

Pleuropulmonary manifestations

 Pleuritis is the most common pulmonary manifestation Can be accompanied with pleural effusion, usually presents with pleuritic chest pain and dyspnoea. Pleural effusion will usually be exudative in nature, rich in neutrophils and monocytes.

 Interstitial fibrosis usually presents with dry cough and progressive dyspnoea. Occurs in smokers and patients with high disease activity.

It is characterised by early inflammatory phase followed later by pulmonary fibrosis. Interstitial lung disease associated with

(19)

rheumatoid arthritis shows good response on treatment with immunological agents.

 Caplan syndrome – characterised by single or multiple pulmonary nodules along with pneumoconiosis can occur after silica exposure

 Bronchiectasis and Bronchiolitis can also in Rheumatoid arthritis patients

Haematological manifestations

 Anaemia is the most common haematological manifestation in rheumatoid arthritis. It will be usually normocytic and normochromic in nature. Cause of anaemia is multifactorial like drug-induced, nutritional, gastrointestinal bleed induced, bone marrow suppression, ineffective erythropoiesis and due to anaemia of chronic disease.

 Lymphocytosis and eosinophilia can occur and can directly reflects disease activity

 Thrombocytosis occurs more commonly than thrombocytopenia

 Lymphadenopathy can occur, usually will be benign as proved by biopsy.

 Felty syndrome – triad of rheumatoid arthritis, splenomegaly and neutropenia occurs in patients with high disease activity and has propensity to develop into Non Hogdkin’s lymphoma. T cell Large

(20)

granulocytic leukemia has also been known to occur in rheumatoid arthritis.

Ophthalmic involvement

 Keratoconjunctivitis sicca occurs most commonly along with xerostomia as a part of secondary sjogren syndrome

 Episcleritis, scleritis, scleromalacia perforens occurs with an incidence of 1 % in Rheumatoid arthritis.

Rheumatoid vasculitis

The development of vasculitis in Rheumatoid arthritis is due to intravascular deposition of immune complexes containing Rheumatoid Factor with immunoglobulin, & associated complement mediated vascular damage.

Usually manifests as

 Petechiae, purpura, Livedo Reticularis

 polyneuropathy and mononeuritis multiplex

 Distal gangrene, skin and deep subcutaneous ulcerations, Nail fold infarcts.

 Visceral infarctions resulting in stroke, MI, mesenteric arteritis.

Occurrence of vasculitis is directly proportional to the occurrence of long standing disease, rheumatoid factor positivity and hypocomplementemia.

(21)

GI And Hepatic manifestations

 Xerostomia, gastritis, peptic ulcer disease

 Nodular regenerative hyperplasia, portal fibrosis

Neurological Manifestations

 Nerve entrapment syndrome (carpal and tarsal tunnel syndrome)

 Spinal compression due to atlanto axial subluxation and Peripheral neuropathy. (due to vasculitis)

(22)
(23)

CARDIOVASCULAR MANIFESTATIONS OF RHEUMATOID ARTHRITIS

Cardiovascular disease is the leading cause of mortality in RA. The majority of increased cardiovascular risk in RA patients was due to accelerated atherosclerosis, independent of other traditional cardiovascular risk factors such as diabetes, dysplipidemia etc. Cause of increased cardiovascular mortality is multifactorial like Inflammation, decreased mobility, dyslipidemia, low levels of antioxidants, increased levels of homocysteine, and side-effects of medication have all been implicated.

Amongst the above causes, inflammation has the strongest association with premature atherosclerosis in RA.

STAGES OF ATHEROSCLEROSIS

ENDOTHELIAL ACTIVATION

ENDOTHELIAL DYSFUNCTION

STAGE OF PREMATURE / SUBCLINICAL ATHEROSCLEROSIS

Finally leads to overt clinical atherosclerosis and development of myocardial infarction, cerebrovascular accident or peripheral vascular disease.

(24)

PATHOGENESIS

Cytokine dysregulation mainly increased cytokines such as TNF – alpha plays main role in vascular inflammation and subsequent atherosclerosis.

(25)

ENDOTHELIAL ACTIVATION

TNF alpha has direct effects on endothelium – usually activates endothelial cell by upregulating various adhesion molecules like VCAM- 1and characterised by influx of inflammatory cells within the vascular wall.

This stage is studied by increase in molecules such as VCAM -1, vonWillebrand factor, osteoprotegrin (decoy for TRAIL), GlyA in serum(newer molecule correlates with coronary calcification)

ENDOTHELIAL DYSFUNCTION

Endothelial dysfunction is recently explained by the TNF alpha induced sphingolipid signalling cascade by release of sphingomyelinase(SMase)

(26)

The main feature of endothelial dysfunction is depression of vasodilator Nitric Oxide, produced by action of eNOS (Ca+ dependent enzyme). TNF alpha induces sphingomyelinase which produces ceramide from sphingosine and depresses Ca+ influx thereby inhibiting eNOS related production of Nitric oxide. This results in the subsequent endothelial dysfunction which is characterised by stiffening of vascular wall.

Arterial stiffness can be measured by the pulse wave analysis visualised in tonometry. In stiff arteries, pulse wave is augmented. Low small artery elasticity is indicative for stiff arteries. Measuring Arterial stiffness by tonometry is a valid method in identifying endothelial dysfunction in Rheumatoid Arthritis.

STAGE OF PRECLINICAL ATHEROSCLEROSIS

Dysfunctional Endothelium is described as the birth place of plaque.

Dysfunction of endothelium favours adhesion of monocytes, provides substrate for deposition of altered lipids and eventually leads to atheromatous plaque formation. The inflammation in vascular wall causes oxidation of low density lipoproteins, which are absorbed by mononuclear cells and transforming them into foam cells.

Carotid Intima Media Thickness is an non-invasive marker to detect subclinical atherosclerosis and can be used as screening test in healthy

(27)

individuals. Increased intima media thickness in carotid arteries holds true for atherosclerosis in multiple vascular beds including coronaries, and so measurement of carotid IMT is an important marker of increased cardiovascular risk.

NON-ATHEROSCLEROTIC CARDIAC MANIFESTATIONS Pericarditis

 Pericarditis is the most common cardiovascular manifestation seen in Rheumatoid Arthritis

 Clinically symptomatic pericarditis occurs rarely while detection of pericarditis with minimal effusion via echocardiography in asymptomatic RA patients is high

(28)

 Symptomatic pericarditis occurs more commonly in male RA patients with high disease activity.

 Constrictive pericarditis and rapidly progressive effusive pericarditis adds to mortality and morbidity in rheumatoid arthritis. It is diagnosed via Transthoracic echocardiography. Cardiac MRI aids in diagnosis of minimal pericardial thickening.

 NSAIDS, corticosteroids, immune suppressive drugs are the drug of choice.

 Severe cases are subjected to pericardiectemy or other surgical treatment

PERICARDIAL EFFUSION IN RHEUMATOID ARTHRITIS PATIENTS

(29)

Rheumatoid Arthritis Cardiomyopathy

 Both ischaemic and nonischaemic secondary cardiomyopathy can occur, the latter being specific due to rheumatoid disease activity.

Cardiomyopathy is very rare when compared to pericardial diseases.

 Can be focal, diffuse necrotising or granulomatous myocarditis.

 Evaluation includes 2D – ECHO and cardiac MRI. Cardiac MRI is helpful in assessing myocardial perfusion which in turn differentiates ischaemic from non-ischaemic cardiomyopathy. Features specific such as increased odema score in T2 weighted imaging, global EF reduction, global late gadolinium enhancement score can be seen.

 Myocarditis may be asymptomatic and self limiting, but can also present with sequalae such as Heart failure, arrhythmias and conduction defects

 Treatment includes Systemic Steroids and DMARDs.

Antimalarial induced cardiomyopathy was an important differential diagnosis and should always be ruled out.

(30)

CARDIAC AMYLOIDOSIS

It is a rare complication of Rheumatoid arthritis leading to Restrictive cardiomyopathy

 Sparkling granular pattern in ECHO suggests Amyloidosis.

 Amyloidosis increases the rate of heart failure in RA patient.

Prognosis is usually poor.

Arrhythmias

 It is the important cause of sudden cardiac death in RA patients

 Arrhythmias may be due to ischemia, rheumatoid nodule, amyloidosis or congestive heart failure

 Atrial arrhythmias, conduction abnormalities and ventricular tachycardia can occur in Rheumatoid arthritis.

 Treatment targeted towards the particular arrhythmia is indicated. No other specific treatment have been proposed

Valve Disease

The pathophysiology behind the development of valvular heart disease in rheumatoid arthritis are 1) Fibrosis, 2) Calcification and 3) Granuloma Formation

(31)

Aortic valve fibrosis

Rheumatoid arthritis patients Mitral Valve Fibrosis in a patient with rheumatoid arthritis

 More commonly affects the left sided valves – mitral being the commonest.

 RA patients are prone to develop mitral regurgitation and aortic regurgitation due to valvulitis and subsequent fibrosis.

 Calcification involving valves – may lead to both stenosis and regurgitation. Rheumatoid nodules also contribute to valvular lesions.

 NonBacterial Thrombotic Endocarditis (NBTE) like Libmann sacks endocarditis has also been associated with Rheumatoid Arthritis like SLE.

Congestive Heart Failure (CHF)

 RA patients are more subjected to Congestive Heart Failure than non RA patients.

(32)

 Increased ESR, rheumatoid vasculitis, rheumatoid lung disease are associated with increased incidence of congestive cardiac failure.

 Smoking, increased BMI, diabetes, ischemic heart diseases and hypertension influence the risk of cardiovascular disease.

 Mostly RA patients don’t complain of anginal symptoms therefore there is high incidence of unrecognised myocardial infection and sudden death in such patients.

 Besides CHF, LV systolic dysfunction has been reported to be 3 times more common than general population.

 Corticosteroids, TNF blockers, methotrexate, NSAIDS and Cox inhibitors are also incriminated in the causation of cardiac dysfunction in RA patients

Coronary Vasculitis

 Non atherosclerotic cause of myocardial ischaemia in rheumatoid arthritis patients is due to coronary vascultis, which is characterised by the inflammation of the vessel wall.

 Involvement of epicardial arteries can lead to presentation of Myocardial infarction similar to that caused by atherosclerosis.

(33)

 It is a life threatening manifestation, which should be treated promptly with immunosuppressive therapy.

DIAGNOSIS OF RHEUMATOID ARTHRITIS

HISTORY

PHYSICAL EXAMINATION

SEROLOGICAL EVIDENCE

IMAGING MODALITIES

SEROLOGY:

RA FACTOR

RA factor is an IgM antibody against the Fc portion of IgG. RA factor and IgG form immune complex deposition responsible for the disease process.

 Sensitivity 60-70%

 Specificity 78%

More than 20 IU/ml is significant. Very high values are associated with greater probability of destructive disease. But, RA factor is nonspecific as it becomes positive in other auto immune diseases,

(34)

ANTI –CCP ANTIBODY

Anti citrullinated protein antibodies are highly specific to RA but not sensitive and it is done in suspected cases with RA factor negativity. Concomitant positivity of RF and ACPA is highly specific to RA. It will be positive in very early disease, and also predict the severity and irreversible damage.

IMAGING:

Bony changes in the imaging may not be seen early in less than 2 year period of disease.

 Changes may start with osteopenia near the joint called as PERIARTICULAR OSTEOPENIA (characteristic feature of Rheumatoid arthritis), soft tissue swelling and smaller joint space.

 Bony erosions and subluxations of joint is seen in advanced disease.

 Ultrasonography may show synovitis and bony erosions in early disease.

 MRI reveals the bone edema in addition to synovitis and bone erosions.

 MRI and USG are more sensitive for early erosive RA.

(35)

SYNOVIAL FLUID ANALYSIS

Reveals high leucocyte count

AMERICAN COLLEGE OF RHEUMATOLOGY CLASSIFICATION CRITERIA FOR RA(2010):

FEATURES SCORE

JOINT INVOLVEMENT:

1 large joint

2 – 10 large joints

1-3 small joints with or without involvement of large joints

4-10 small joints with or without involvement of large joints

>10 joints( atleast 1 small joint )

0 1 2 3 5

SEROLOGY:

Negative RF and negative ACPA Low positive RF or Low positive ACPA

High positive RF or High positive ACPA

0 2 3

ACUTE PHASE REACTANTS:

Normal CRP and Normal ESR Abnormal CRP or Abnormal ESR

0 1 DURATION OF SYMPTOMS:

<6 weeks

≥6 weeks

0 1

(36)

INFERENCE:

Score ≥6/10 – definite RA

RHEUMATOID ARTHRITIS DISEASE ACTIVITY MEASURES

The American College of Rheumatology (ACR) have recommended various scoring systems to use in Rheumatoid arthritis patients for assessing the disease activity in them and to use in clinical practice. The scoring systems used are,

1. CDAI score ( Clinical Disease Activity Index Score)

2. DAS -28 score –ESR/CRP ( Disease Activity Score with 28 joint counts)

3. PAS (Patient Activity Scale) 4. PAS –II

5. RAPID – 3 (Routine assessment of Patient Index Data with 3 measures)

6. SDAI (Simplified Disease Activity Index)

CLINICAL DISEASE ACTIVITY INDEX SCORE (CDAI score)

The CDAI score were developed in order to provide quantifiable measures of Rheumatoid arthritis activity. Calculated using the formula

(37)

CDAI = SJC(28) + TJC(28) + PGA + EGA. (SJC and TJC denotes swollen, tender joints respectively. PGA and EGA are patient and evaluator global assessment scale which ranges from 1-10 each)

An reduction of CDAI score by 6.5 represents moderate improvement.

MERITS:

In contrast to DAS- 28 score and SDAI score which uses CRP in their assessment, CDAI can be used as a pure clinical score without adding any laboratory investigations, used in clinical practice.

DEMERITS:

Does not include Ankle and foot joints

(38)

CALCULATION FORMULAS FOR VARIOUS DISEASE ACTIVITY SCORING SYSTEMS

Table 4. Formulas for measurement tools*

Measurement tool Formula

CDAI 28SJC 28TJC PrGA PtGA

DAS28

DAS28-ESR 0.56(28TJC) 0.28(28SJC) 0.70 ln(ESR) 0.014 PtGA

DAS28-CRP 0.56(28TJC) 0.28(28SJC) 0.36 ln(CRP 1) 0.014 PtGA 0.96

PAS (HAQ 3.33 pain VAS PtGA VAS)/3 PAS-II (HAQ-II 3.33 pain VAS PtGA VAS)/3 RAPID-3 (MDHAQ 3.33 pain VAS PtGA VAS)/3

SDAI 28SJC 28TJC PrGA PtGA CRP

* Numerical rating scales may be substituted for visual analog scales (VAS) in all measures. CDAIClinical Disease Activity Index; 28SJC28 swollen joint count; 28TJC 28 tender joint count; PrGA provider global assessment of disease activity; PtGA patient global assessment of disease activity;

DAS28 Disease Activity Score with 28-joint counts; ESR erythrocyte sedimentation rate; CRP C-reactive protein; PAS Patient Activity Scale;

HAQ Health Assessment Questionnaire; RAPID-3 Routine Assessment of Patient Index Data with 3 measures; MDHAQ Multidimensional HAQ;

SDAI Simplified Disease Activity Index.

(39)

COMPARISON OF DISEASE SEVERITY BY VARIOUS SCORING SYSTEMS

TREATMENT:

Rheumatoid arthritis causes irreversible damage and hence it is necessary to get treated as early as possible.

The various modalities of treating RA are as follows:

NON PHARMACOLOGICAL PHARMACOLOGICAL

SURGICAL THERAPY Instruments Remission Low

Activity Moderate

Activity High Activity DAS-28

(range 0 to 9.4) < 2.6 ≥2.6 to < 3.2 ≥ 3.2 to≤5 > 5.1 SDAI

(range 0 to 86.0) ≤3.3 > 3.3 to≤11 > 11 to≤26 > 26 CDAI

(range 0 to 76) ≤2.8 > 2.8 to 10.0 >10.0 to 22 > 22

(40)

NON PHARMACOLOGICAL:

 PHYSICAL THERAPIES

 OCCUPATIONAL THERAPIES

 PSYCHOTHERAPY

PHYSICAL THERAPIES

Therapies such as splinting of joints, heat therapy and joint range of motion exercise are used to prevent joint stiffness that limits many patients with RA.

PHARMACOLOGICAL THERAPY:

Goals of drug therapy:

 Ameliorate pain, swelling and joint stiffness

 Prevent articular damage and bony erosion

 Prevent deformity and preserves joint functions

(41)

NOS. DRUGS MOA ADVERSE

EFFECTS INDICA TIONS

1 NSAIDs

(aspirin) and corticosteroids

Suppression of inflammation and immunosuppression

Steroid induced

osteoporosis early RA

2. DMARDS

Reduces inflammation and prevents damage to

joints, bones and ligaments

GI intolerance, hepatotoxicity,

alopecia, homocystinemia

First line drugs

3. Biological agents

Blocks immune response leading to

RA

Pruritis, influenza like

symptoms, headache, hypotension

NSAIDS AND CORTICOSTEROIDS

Aspirin and low dose corticosteroids are used in early RA.

Used for symptomatic relief. 5-10 mg (low dose) prednisolone are used to supplement or substitute NSAIDs. Low dose steroids are also used as bridge therapy before starting biological therapy/DMARDs. If steroids are used for long term (> 3 months), prophylactic therapy with bisphosphonates for osteoporosis should be started.

(42)

INTRA- ARTICULAR STEROIDS

In cases with single or few joint involvement, intra - articular injection of a soluble glucocorticoid affords relief and slows down the joint damage.

Treatment of choice in acute flare (monoarticular) of Rheumatoid arthritis.

DISEASE MODIFYING ANTI-RHEUMATIC AGENTS

They are called so due to their ability to prevent or slow the progression of disease both structurally and functionally.

There are 2 types namely

CONVENTIONAL DMARDS – immunosuppressants, sulfasalazine, leflunomide, Hydroxychloroquine

BIOLOGICAL- TNFα Inhibitors, Anakinra, Abatacept, Rituximab, Tocilizumab & Newer drugs.

METHOTREXATE:

 It inhibits production of cytokines; chemotaxis and cell mediated immune response.

 Exerts anti-inflammatory effect by releasing adenosine from cells.

 Starting dose – 7.5 to 10mg/week orally.

(43)

 To reduce the adverse effects, folic acid 5mg once a week is given

HYDROXYCHLOROQUINE:

 Has moderate effect, used in mild or early disease

 Used as adjunctive therapy with other DMARDs

 Cardiac and retinal toxicity are major side effects LEFLUNOMIDE:

 It inhibits dihydroorotate dehydrogenase and pyrimidine synthesis in actively dividing cells.

 Dosage- 10 to 20mg/day.

 Can be used as monotherapy or in combination with methotrexate

Other drugs such as sulfasalazine, minocycline, pencillamine, azathioprine, cyclosporine , gold salts has also been used as DMARDs.

BIOLOGICAL AGENTS:

It includes

TNF α inhibitors (Infliximab, Adalimumab, Etanercept,

(44)

IL – 1 antagonists (Anakinra)

Anti- CD20 B cell agents(Rituximab)

Anti- IL 6 agents (Tocilizumab) INFLIXIMAB:

 It is a IgG1 chimeric monoclonal antibody which is administered at a initial dose of 3mg/kg i.v over 2 hrs.

 Soft tissue and joint infections, fungal infections, demyelination and reactivation of TB can occur as side effects.

ETANERCEPT:

 It is the recombinant fusion protein of TNF receptor and Fc portion of human IgG.

 Administered by s.c. injection 50mg weekly.

 Pain, redness, itching at the injection site can occur.

ANAKINRA

Used in juvenile onset inflammatory arthritis ABATACEPT

 It is a soluble fusion protein containing CTLA -4 and human

(45)

 It inhibits costimulatory molecules CD28/80 and thereby prevents T cell activation.

 Reduces disease activity and retards progression of disease.

RITUXIMAB

 Used for treatment of refractory Rheumatoid arthritis.

 Usually used in combination with methotrexate, provides good results.

 Infusion reactions and Progressive multifocal leuko encephalopathy are the major side effects.

TOCILIZUMAB

It is the IL-6 receptor monoclonal antibody used in Rheumatoid arthritis, as IL-6 plays important role in pathogenesis of RA.

TOFACITINIB

Newer drug which inhibits JAK 1 and 3, thereby blocks cytokines such as IFN – gamma and IL-6.

SURGICAL THERAPY:

It is indicated for patients with destructive rheumatoid arthritis.

The various surgical methods include

(46)

 Arthroplasty

 Joint replacement surgeries

 Synovectomy

(47)

MTX+ NSAIDs First Line

In 12% of the cases, physicians could switch from

one of the products, mainly from NSAIDs for the first line to

Hydroxychloroquine or Steroids

MTX or NSAID HQ or Steroid+

In most of the cases, physicians add Hydroxychloroquine or

Steroids

to the products for the first line

MTX + NSAIDs HQ or Steroids+ Second Line

Biologics + Sometimes, physicians

switch from the second line therapy to the biologics and they use them as monotherapy in

third line

More often, the biologics are added to the MTX containing regimens and

they are used in combination in third line

therapy

Reasons for switching to

another medication are in 100% of the cases

the inadequate response to the

previous one.

Adding another medication is always due to the inadequate

response to the previous one.

Physicians take

also into

consideration the ability of the

(48)

MATERIALS AND METHODS

Sample Size: 50

Type of Study : Prospective Cross sectional Study

Duration of Study: 12 months ( April 2017 to April 2018) Inclusion Criteria

 Patients more than 16 years of age

 Known Rheumatoid Arthrithis patients who have been clinically examined and investigated and found to be fulfilling the American College of Rheumatology criteria for Rheumatoid arthritis 2010 Exclusion Criteria

 Rheumatoid arthritis Patients with known Overt cardiovascular disease like coronary artery disease, cerebrovascular disease, peripheral vascular disease

 Rheumatoid arthritis patients with other independent risk factors for developing cardiovascular diseases such as Diabetes, Hypertension, Smoking and alcoholism

 Patients less than 16 years of age

(49)

 Patients not fulfilling the American College of Rheumatology criteria for Rheumatoid Arthritis 2010.

 Rheumatoid Arthritis patients not willing to participate in the study.

Methodology

This prospective cross sectional study is carried out in known Rheumatoid Arthritis patients attending General Medicine & Rheumatology outpatient clinic or ward of Tirunelveli Medical College Hospital between April 2017 and April 2018. They have been selected after detailed investigations and found to be fulfilling ACR criteria for Rheumatoid Arthritis 2010 and also the inclusion , exclusion criteria of our case study.

Written informed consent was obtained from the patients selected for the study. They have been subjected to detail clinical and laboratory investigations. Routine investigations such as complete blood count, Hemoglobin, Total leukocyte count, Differential count, Platelet count, Renal Function test, Liver Function Test, Serum Electrolytes, Fasting Lipid Profile , Urine Routine Investigations and Blood sugar.

In addition, investigations such as ESR, CRP, RA factor, Anti- CCP antibody, Electrocardiogram, Chest X-Ray PA view, Echocardiogram and Carotid Doppler to detect Carotid Intima Media Thickness were done for all

(50)

Carotid Intima Media Thickness was assessed by Ultrasonagraphy B – Mode with a probe of frequency 5 Hz and was confirmed with colour Doppler sonography. Intima Media Thickness was measured at three sites - along common carotid artery in the distal 1 cm before its bifurcation, at the carotid bulb, and at the internal carotid artery. Measurements are taken at diastole, at both sides and the average of six measurements were taken which denotes the mean Carotid Intima Media Thickness of the patient.

Clinical Disease Severity Index score (CDAI score ) was calculated for all selected patients in the study which denotes the disease severity and activity in the patient. It was calculated using the formula,

CDAI = SJC(28) + TJC(28) + PGA + EGA.

Whereas

 SJC denotes swollen joint count(28) ,

 TJC denoted tender joint count(28) ,

 PGA denotes Patient Global disease activity scale and

 EGA denotes Evaluator’s Global disease activity scale , latter two ranging from 1-10.

Interpretation was made by studying the occurrence of various clinical

(51)

correlating them with the disease activity and severity in those patients which is assessed by the CDAI score.

(52)

RESULTS

DEMOGRAPHIC DISTRIBUTION

TABLE NO 1 : AGE DISTRIBUTION

Our study group consists of 50 Rheumatoid arthritis patients who fell in age group of 21 -74 yrs

FIGURE NO 1: AGE DISTRIBUTION

AGE GROUP NO OF PATIENTS

<30 3

30-50 24

>50 23

3

24 23

0 5 10 15 20 25 30

<30 30-50 >50

(53)

TABLE NO 2 : GENDER DISTRIBUTION

GENDER NO OF PATIENTS

Male 9

Female 41

FIGURE NO 2 : GENDER DISTRIBUTION

Male, 9

Female, 41

(54)

TABLE NO 3 : DISTRIBUTION OF JOINT INVOLVEMENT

JOINT INVOLVEMENT NO OF PATIENTS

MCP 46

PIP 33

Wrist 32

Knee 10

Elbow 15

Shoulder 4

Ankle 8

RA hand 3

FIGURE NO 3 : DISTRIBUTION OF JOINT INVOLVEMENT

46

33 32

10

15

4

8

3 0

5 10 15 20 25 30 35 40 45 50

MCP PIP Wrist Knee Elbow Shoulder Ankle RA hand

(55)

TABLE NO 4 : DISTRIBUTION OF DISEASE DURATION

DISEASE DURATION NO OF PATIENTS

< 5 years 15

5-10 years 11

10-15 years 16

> 15 years 8

FIGURE NO 4 : DISTRIBUTION OF DISEASE DURATION

15

11

16

8

0 2 4 6 8 10 12 14 16 18

< 5 years 5-10 years 10-15 years > 15 years

(56)

TABLE NO 5: DISTRIBUTION OF TREATMENT DURATION

TREATMENT DURATION NO OF PATIENTS

Not on Treatment 1

< 10 years 29

>10 years 20

FIGURE NO 5 : DISTRIBUTION OF TREATMENT DURATION

Not on treatment , 1

< 10 years, 29

>10 years, 20

(57)

TABLE NO 6: DISTRIBUTION OF ANAEMIA IN STUDY GROUP

HAEMOGLOBIN (G / dl) NO OF PATIENTS

>11 14

9-11 15

7-9 15

<7 6

FIGURE NO 6 : DISTRIBUTION OF ANAEMIA IN STUDY GROUP

14

15 15

6

0 2 4 6 8 10 12 14 16

>11 9-11 7-9 <7

(58)

TABLE NO 7 : VARIATION IN TOTAL LEUCOCYTE COUNT IN STUDY GROUP

TOTAL LEUCOCYTE COUNT NO OF PATIENTS

Normal 45

Leucocytosis 3

Leucopenia 2

FIGURE NO 7 : VARIATION IN TOTAL LEUCOCYTE COUNT IN STUDY GROUP

Normal, 45 Leucocytosis, 3Leucopenia, 2

(59)

TABLE NO 8 : LYMPHOCYTOSIS IN STUDY GROUP

DIFFERENTIAL COUNT NO OF PATIENTS

LYMPHOCYTOSIS 10

NORMAL LYMPHOCYTE COUNT 40

FIGURE NO 8: LYMPHOCYTOSIS IN STUDY GROUP

Normal, 40 Lymphocytosis, 10

(60)

TABLE NO 9 : PLATELET COUNT DISTRIBUTION IN STUDY GROUP

PLATELET COUNT NO OF PATIENTS

Thrombocytopenia 7

Normal 41

Thrombocytosis 2

FIGURE NO 9: PLATELET COUNT DISTRIBUTION IN STUDY GROUP

Normal, 41 Thrombocytopeni

a, 7

Thrombocytosis, 2

(61)

TABLE NO 10: DYSLIPIDEMIA IN STUDY GROUP

LIPID PROFILE NO OF PATIENTS

Normal 43

Hypercholesterolemia 5

Hypertriglyceridemia 2

FIGURE NO 10: DYSLIPIDEMIA IN STUDY GROUP

Normal, 43 HyperCholesterole

mia, 5

Hypertriglyceridem ia, 2

(62)

TABLE NO 11 : ESR CORRELATION IN STUDY POPULATION

ESR NO OF PATIENTS

< 20 2

20-50 15

50-70 23

> 70 10

FIGURE NO 11 : ESR CORRELATION IN STUDY POPULATION

< 20 4%

20-50 30%

50-70 46%

> 70 20%

ESR

(63)

TABLE NO 12 : CRP CORRELATION IN STUDY POPULATION

CRP NO OF PATIENTS

Positive 23

Negative 27

FIGURE NO 12: CRP CORRELATION IN STUDY POPULATION

Positive , 23 Negative, 27

(64)

TABLE NO 13: ECG CHANGES IN STUDY GROUP

ECG CHANGES NO OF PATIENTS

Right axis duration 4

Left axis duration 15

RBBB 11

LAFB 2

LVH 5

Left Atrial enlargement 2

Nonspecific ST-T changes 12

Coronary artery disease / specific ST-T changes

9

ARRHYTHMIA (BradyArrhythymia /

TachyArrhythymia)

3

Normal 12

Low voltage complexes 5

(65)

TABLE NO 13: ECG CHANGES IN STUDY GROUP

4

15 11

2

5 2

12 9

3

12 5

0 2 4 6 8 10 12 14 16

Right axis duration Left axis duration RBBB

LAFB LVH Left Atrial enlargement Nonspecific ST-T changes Coronary artey disease / specific ST-T changes Arrythmias (Brady / Tachy)

Normal Low voltage complexes

(66)

TABLE NO 14: X-RAY CHANGES IN STUDY POPULATION

CHEST X-RAY CHANGES NO OF PATIENTS

Normal 26

Cardiomegaly 20

Other changes 4

FIGURE NO 14: X-RAY CHANGES IN STUDY POPULATION

Normal , 26 Cardiomegaly ,

20

others, 4

(67)

TABLE NO 15: CDAI SCORE DISTRIBUTION

The disease severity was high among our study group with 60 % of cases occupying High CDAI score with no patients under remission.

CDAI SCORE NO OF PATIENTS

Remission <2.8 Nil

Low 2.8 – 10 3

Moderate 10-22 17

High > 22 30

FIGURE NO 15: CDAI SCORE DISTRIBUTION

3

17

30

0 5 10 15 20 25 30 35

Low Moderate High

(68)

TABLE NO 16: MEAN CIMT DISTRIBUTION IN STUDY GROUP

MEAN CIMT NO OF PATIENTS

Increased CIMT 34

Normal 12

Plaque 4

FIGURE NO 16: MEAN CIMT DISTRIBUTION IN STUDY GROUP

12

34

4

0 5 10 15 20 25 30 35 40

Normal Increased CIMT Plaque

(69)

TABLE NO 17: DESCRIPTIVE STATISTICS

Mean age, Duration of disease, CDAI score, ESR, CRP, mean CIMT, mean EF in our study population were listed.

N Minimum Maximum Mean Std. Deviation

Age 50 21.00 74.00 47.76 11.09

CDAI_Score 50 5.00 44.00 25.16 10.40

Duration 50 .20 20.00 8.63 5.85

CIMT 50 0.00 .99 0.72 0.26

EF 50 38.00 75.00 59.46 9.25

ESR 50 15.00 120.00 49.50 27.97

CRP 50 1.00 2.00 1.46 0.50

(70)

TABLE NO 18: CORRELATION OF MEAN CAROTID INTIMA MEDIA THICKNESS IN STUDY POPULATION

Mean CIMT of study population was correlated with various parameters such as Age of patient, Duration of disease, Duration of treatment, ESR and CDAI score.

Correlation Coefficient P value

CIMT

Age 0.136 0.347

Duration of RA 0.342 0.015

CDAI 0.187 0.043

ESR 0.05 0.732

Duration of Treatment 0.364 0.010

(71)

FIGURE NO 18: CORRELATION OF MEAN CAROTID INTIMA MEDIA THICKNESS VS CDAI SCORE

There is a significant relationship between the mean Carotid Intima Media Thickness (CIMT) and Clinical Disease Activity Index (CDAI) score.

(p value 0.043)

(72)

FIGURE NO 19: CORRELATION OF MEAN CAROTID INTIMA MEDIA THICKNESS VS DISEASE DURATION

There is a significant relationship between the mean Carotid Intima Media Thickness (CIMT) and Duration of Rheumatoid Arthritis, Duration of treatment (p value of 0.015, 0.010 respectively.)

There is no significant relationship between mean Carotid Intima Thickness (CIMT) and Age of the patient and ESR values (p value 0.347, 0.732

(73)

TABLE NO 19: CIMT CORRELATION WITH C-REACTIVE PROTEIN LEVELS

CRP N Mean

Std.

Deviation P value

CIMT Negative 27 0.71 0.19

0.603

Positive 23 0.74 0.33

There is no significant relationship between mean Carotid Intima media Thickness (CIMT) and C-Reactive Protein Levels

DISTRIBUTION OF ECHOCARDIOGRAPHIC FINDINGS IN STUDY POPULATION

The distribution of various echocardiographic findings such as Left Venticular Systolic Function, Left Ventricular Diastolic function, Pericardial Effusion, Pulmonary Hypertension, Valvular Abnormalities such as Mitral Regurgitation, Aortic sclerosis, coronary calcifications were listed.

(74)

TABLE NO 20: LV SYSTOLIC DYSFUNCTION DISTRIBUTION

Frequency Percent Valid Percent

Cumulative Percent

Valid No 42 84.0 84.0 84.0

Yes 8 16.0 16.0 100.0

Total 50 100.0 100.0

TABLE NO 21: LV DIASTOLIC DYSFUNCTION DISTRIBUTION

Frequency Percent Valid Percent

Cumulative Percent

Valid No 28 56.0 56.0 56.0

Yes 22 44.0 44.0 100.0

Total 50 100.0 100.0

TABLE NO 22: PERICARDIAL EFFUSION DISTRIBUTION

Frequency Percent Valid Percent

Cumulative Percent

Valid No 37 74.0 74.0 74.0

Yes 13 26.0 26.0 100.0

Total 50 100.0 100.0

(75)

TABLE NO 23: PULMONARY HYPERTENSION DISTRIBUTION

Frequency Percent

Valid Percent

Cumulative Percent

Valid No 46 92.0 92.0 92.0

Yes 4 8.0 8.0 100.0

Total 50 100.0 100.0

TABLE NO 24: MITRAL REGURGITATION DISTRIBUTION

Frequency Percent

Valid Percent

Cumulative Percent

Valid No 40 80.0 80.0 80.0

Yes 10 20.0 20.0 100.0

Total 50 100.0 100.0

TABLE NO 25: AORTIC SCLEROSIS DISTRIBUTION

Frequency Percent

Valid Percent

Cumulative Percent

Valid No 45 90.0 90.0 90.0

Yes 5 10.0 10.0 100.0

Total 50 100.0 100.0

(76)

TABLE NO 26: CORONARY CALCIFICATION DISTRIBUTION

Frequency Percent

Valid Percent

Cumulative Percent

Valid No 48 96.0 96.0 96.0

Yes 2 4.0 4.0 100.0

Total 50 100.0 100.0

FIGURE NO 26: DISTRIBUTION Of ECHO CARDIO GRAPHIC FINDINGS

16%

44%

26%

8%

20%

10%

4%

0%

5%

10%

15%

20%

25%

30%

35%

40%

45%

50%

Percentage of Patients

(77)

CORRELATION OF ECHOCARDIOGRAPHIC FINDINGS WITH CLINICAL DISEASE ACTIVITY INDEX SCORE

TABLE NO 27: EJECTION FRACTION vs CDAI SCORE

Correlation Coefficient P value

EF CDAI Score 0.311 0.030

There is significant relationship between variation in ejection fraction and Clinical Disease activity index score (p value 0.030)

TABLE NO 28: LEFT VENTRICULAR SYSTOLIC DYSFUNCTION vs CDAI SCORE

LVSD N Mean Std.

Deviation

P value

CDAI_Score No 42 22.93 9.56 <0.0001

Yes 8 36.88 5.87

There is strong correlation between Left Ventricular Systolic Dysfunction and Clinical Disease Severity Index score (p value < 0.0001)

(78)

TABLE NO 29: LEFT VENTRICULAR DIASTOLIC DYSFUNCTION vs CDAI SCORE

LVDD N Mean Std.

Deviation

P value

CDAI_Score No 28 23.46 11.35 0.196

Yes 22 27.32 8.83

There is no significant relationship between left ventricular diastolic dysfunction and Clinical Disease activity index score (p value 0.196)

TABLE NO 30: PERICARDIAL EFFUSION vs CDAI SCORE

PERICARDIAL EFFUSION

N Mean Std.

Deviation

P value

CDAI_Score No 37 22.86 10.60 0.007

Yes 13 31.69 6.47

There is significant relationship between occurrence of pericardial effusion and Clinical Disease Severity Index score (p value 0.007 )

(79)

TABLE NO 31: PULMONARY HYPERTENSION vs CDAI SCORE

PULMONARY HYPERTENSION

N Mean Std.

Deviation

P value

CDAI_Score No 46 25.17 10.51 0.975

Yes 4 25.00 10.39

There is no significant relationship between occurrence of Pulmonary hypertension and Clinical Disease Severity Index score (p value 0.975).

TABLE NO 32: MITRAL REGURGITATION vs CDAI SCORE

MITRAL REGURGITATION

N Mean Std.

Deviation

P value

CDAI_Score No 40 23.88 10.01 0.080

Yes 10 30.30 10.87

There is no significant relationship between occurrence of Mitral regurgitation and Clinical Disease Severity Index score (p value 0.080).

(80)

TABLE NO 33: AORTIC SCLEROSIS vs CDAI SCORE

AORTIC SCLEROSIS N Mean Std.

Deviation

P value

CDAI_Score No 45 25.84 10.35 0.165

Yes 5 19.00 9.62

There is no significant relationship between occurrence of Aortic Sclerosis and Clinical Disease Severity Index score (p value 0.165).

TABLE NO 34: CORONARY CALCIFICATIONS vs CDAI SCORE

CORONARY CALCIFICATIONS

N Mean Std.

Deviation

P value

CDAI_Score No 48 24.96 10.57 0.507

Yes 2 30.00 1.41

There is no significant relationship between occurrence of coronary calcifications and Clinical Disease Severity Index score (p value 0.507).

(81)

CORRELATION OF ECHOCARDIOGRAPHIC FINDINGS WITH DURATION OF RHEUMATOID ARTHRITIS

TABLE NO 35: EJECTION FRACTION vs DURATION OF RHEUMATOID ARTHRITIS

Correlation Coefficient P value

EF Duration of disease -0.516 <0.0001

There is strong significant relationship between variation in ejection fraction and duration of rheumatoid arthritis (p value < 0.0001).

TABLE NO 36: LEFT VENTRICULAR SYSTOLIC DYSFUNCTION vs DURATION OF RHEUMATOID ARTHRITIS

LVSD N Mean Std.

Deviation

P value

Duration of disease

No 41 5.62 3.98 0.003

Yes 8 10.50 3.82

There is strong significant relationship between left ventricular systolic

(82)

TABLE NO 37: LEFT VENTRICULAR DIASTOLIC

DYSFUNCTION vs DURATION OF RHEUMATOID ARTHRITIS

LVDD N Mean Std.

Deviation

P value

Duration of disease

No 28 5.20 4.62 0.021

Yes 21 8.05 3.34

There is strong significant relationship between left ventricular diastolic dysfunction and duration of rheumatoid arthritis (p value 0.021).

TABLE NO 38: PERICARDIAL EFFUSION vs DURATION OF RHEUMATOID ARTHRITIS

PERICARDIAL EFFUSION

N Mean Std.

Deviation

P value

Duration of disease

No 37 6.29 4.65 0.707

Yes 12 6.83 3.24

There is no significant relationship between occurrence of pericardial effusion and duration of rheumatoid arthritis (p value 0.707).

(83)

TABLE NO 39: PULMONARY HYPERTENSION vs DURATION OF RHEUMATOID ARTHRITIS

PULMONARY HYPERTENSION

N Mean Std.

Deviation

P value

Duration of disease

No 45 6.64 4.44 0.246

Yes 4 4.00 1.15

There is no significant relationship between occurrence of Pulmonary hypertension and duration of rheumatoid arthritis (p value 0.246).

TABLE NO 40:MITRAL REGURGITATION vs DURATION OF RHEUMATOID ARTHRITIS

MITRAL REGURGITATION

Mean Std.

Deviation

P value

Duration of disease

No 39 5.68 4.12 0.016

Yes 10 9.32 4.01

There is significant relationship between occurrence of Mitral Regurgitation and duration of rheumatoid arthritis (p value 0.016).

(84)

TABLE NO 41: AORTIC SCLEROSIS vs DURATION OF RHEUMATOID ARTHRITIS

AORTIC SCLEROSIS N Mean Std.

Deviation

P value

Duration of disease

No 44 5.99 4.25 0.038

Yes 5 10.20 3.19

There is significant relationship between occurance of Aortic sclerosis and duration of rheumatoid arthritis (p value 0.038).

TABLE NO 42: CORONARY CALCIFICATIONS vs DURATION OF RHEUMATOID ARTHRITIS

CORONARY CALCIFICATIONS

N Mean Std.

Deviation

P value

Duration of disease

No 47 6.44 4.33 0.890

Yes 2 6.00 5.66

There is no significant relationship between occurrence of coronary calcifications and duration of rheumatoid arthritis (p value 0.890).

(85)

DISCUSSION

We found that patients among our study group fell in age group of 21- 74 yrs with mean age of 47.76 years. Males among study group occupy 28%

& females 72 % respectively. The Mean duration of rheumatoid arthritis among study population is 8.63 ± 5.85 yrs.

The disease severity among patients was assessed with clinical disease severity score and Mean CDAI score among them are 25.16 ± 10.4.

The disease severity was high among our study group with 60 % of cases occupying High CDAI score with no patients under remission.

Metacarpophalangeal, proximal interphalangeal joint and wrist joints are the most commonly involved joints among study population.

Anaemia seems to be occur more commonly in rheumatoid arthritis patients, being in 72 % of our study population. Lymphocytosis were found in 20% of our study group. Thrombocytopenia and thrombocytosis occurs in minority group of patients (14 %, 4% respectively).

Dyslipidemia in form of Hypercholesterolemia and hypertriglyceridemia was found in 10% and 4% of our study population respectively.

(86)

Markers of inflammation such as ESR and CRP are raised more commonly among rheumatoid arthritis patients, ESR being more commonly raised in 96 % of patients, and CRP raised in 46 % of patients in study group.

Most Common ECG abnormality found in study group was Left axis deviation (30%) followed by nonspecific ST-T changes (24%). ST –T changes suggestive of coronary artery disease in asymptomatic patients of our study group was found in 18 % of individuals, which was comparable to Masooleh SI et al(21) in which 15% cases had ST-T changes .

In chest X-ray screening, cardiomegaly was found in 40 % of patients and other abnormalities such as fibrotic changes in lungs, prosthetic heart valve shadows, bronchiectactic changes in lungs were present in minority of patients.

Mean Carotid Intima media thickness (CIMT) (cut off among normal individuals is 0.57 mm) is increased in Rheumatoid Arthritis patients when matched with age related controls which signifies presence of premature atherosclerosis. In our case series, Mean CIMT was found to be increased in 68 % of patients. Asymptomatic Carotid Plaque was present in 8% of patients. Presence of carotid plaque suggests that the patients are in stage of preclinical atherosclerosis and emphasis the need for more aggressive risk reduction strategies in these patients.

(87)

ECHOCARDIOGRAPHIC FINDINGS

In our study group, Echo abnormalities were found in 68 % of patients.

In our case series, Most common Echocardiographic abnormality is LV diastolic dysfunction which contributes 44% of study group, comparable to 14.54%in study conducted by Raof RM et al(24)followed by Pericardial effusion contributing to 26 %, which was comparable to the study conducted by Selcuket al(28 ) in which it was 15%. .High prevalence of this complication (47%) was found in study done by Masooleh SI et al(21).

Other abnormalities such as Mitral Regurgitation , LV systolic dysfunction were present in 20 % and 16 % of study population respectively, whereas it was as high as 31%(LVSD) in the study by Dawson et al. Coronary calcifications were found in 2 patients.

ESR correlates positively with Clinical disease activity Index score, duration of Rheumatoid arthritis & Mean Carotid Intima Media Thickness.

This proves that increased CIMT was associated with inflammatory burden due to more severe disease, and also the chronic inflammation which reflects the duration of the disease.

Dyslipidemia & CRP shows no significant correlation with CIMT or

(88)

Mahajan et al. [10] who did not find significantly correlated dyslipidaemia with accelerated atherosclerosis in RA patients.

According to Homa et al, CIMT increases linearly from 0.48 mm at 40 years of age to 1.02 mm at 100 years of age.

Mean age group in our study was 47.76 yrs & mean CIMT was 0.72 mm So, In our study group CIMT was higher than age related controls and correlates positively with severity of disease as evidenced by high CDAI score( p value 0.043) & duration of disease(p value 0.015), similar observation made by Gonzalez et al and Alkabbi et al in their respective studies. In an Indian study, Mahajan et al. also showed similar observations which showed higher CIMT values in RA patients when compared to control group matched age and related parameters. [10].

Among echocardiographic findings, LV systolic dysfunction (LVSD), variation in Ejection Fraction and Pericardial Effusion positively correlates with clinical disease severity index (CDAI) score in our study group.

Left Ventricular Systolic Function, Left Ventricular Diastolic Dysfunction, and valvular abnormalities such as Mitral Regurgitation and Aortic sclerosis correlates positively with duration of rheumatoid arthritis.

(89)

Coronary Calcification was found in 4 % patients in our study, was an indirect marker of subclinical atherosclerosis and serves as a marker of cardiovascular events. In our case series, Coronary calcification has no significant association with disease severity and duration of disease, in contrast to the study by Giles et al., which shows increasing disease severity in RA is associated with increased prevalence and extent of coronary calcification, irrespective of gender and age.

(90)

CONCLUSION

Cardiovascular abnormalities such as nonatherosclerotic features like LV diastolic & systolic dysfunction , valvular abnormalities, pericardial effusion and mainly premature atherosclerosis occurs commonly in Rheumatoid arthritis patients & their occurrence positively correlates with Clinical disease activity Index (CDAI)score, disease duration and treatment duration.

All Rheumatoid arthritis patients should be screened for CVS abnormalities through modalities like Electrocardiography, Echocardiography & CIMT periodically. CIMT, a non-invasive marker of accelerated atherosclerosis is also a marker of coronary atherosclerosis serves as an important tool in developing countries like India , due to its low cost, non-invasive patient convenient procedure and so has been recommended by American Heart Association (AHA) as a screening test for cardiovascular diseases in apparently healthy individuals.

DMARDs & Biological agents have been shown to have cardio protective effects in many studies. In a study cohort, Methotrexate have shown to reduce cardiovascular morbidity and mortality, ranging from 15%

to 85%.Biological Agents such as TNF alpha inhibitor therapy improves endothelial function and arterial stiffness in patients with RA as shown in a

(91)

Tocilizumab (IL -6 inhibitor) and Rituximab improves both endothelial function and arterial stiffness, also reduces carotid atherosclerosis respectively.

Therefore, Early identification & effective control of disease activity by DMARDS/Biological agents at correct time can prevent or halt the progression of cardiovascular manifestations in Rheumatoid arthritis patients thereby reducing the mortality and morbidity caused by them.

(92)

LIMITATION

1. The Study population is too small

2. History of usage of drugs such as DMARDs or Biological agents were not obtained

3. Effects of patients medication for rheumatoid arthritis on patients disease severity and its influence and correlation on cardiovascular manifestations were not studied.

4. RA Factor and Anti-CCP antibody titre levels were not correlated with patients cardiovascular manifestations.

References

Related documents

The present study was carried out to correlate serum Prolactin levels with disease activity in recently diagnosed Rheumatoid Arthritis patients.. A case-control study was carried

the disease activity scale (DAS28) and radiological severity scale (Van der Heijde modification of Sharp score) in patients who present with rheumatoid arthritis.. This study

Describing the clinical features, laboratory profile, radiological patterns, pulmonary function test (PFT) abnormalities and broncho-alveolar lavage (BAL) cytology of

1) To study the Serum Fasting Lipid Profile Pattern in Rheumatoid arthritis. 2) To estimate subclinical atherosclerosis in patients suffering from rheumatoid arthritis

Textbook of the Autoimmune diseases. RG Lahita, N Chirozzi and WH Reeves). Lippinkot Williams &amp; Wilkins, Philadelphia, 2000, pp.. 38) Adler Y, Finkelstein Y, Zandeman-Goddard

The principal application of electrical studies to rheumatic diseases is in the diagnostic and prognostic assessment of the neurological and myopathic features that can complicate

a) To identify and analyze the common presenting complaints of rheumatoid arthritis patients like loss of appetite, fever and fatigability. b) To assess the various joint

Objective: Clinical involvement of the peripheral nervous system is uncommon in rheumatoid arthritis (RA); the most common disorders are multiple mononeuritis, sensorimotor